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RESEARCH ARTICLE
RNA expression of TLR10 in normal 
equine tissues
Rachael E. Tarlinton1* , Lauren Alder1, Joanna Moreton1,2, Grazieli Maboni1, Richard D. Emes1,2 
and Sabine Tötemeyer1
Abstract 
Background: Toll like receptors are one of the major innate immune system pathogen recognition systems. There is 
little data on the expression of the TLR10 member of this family in the horse.
Results: This paper describes the genetic structure of the Equine TLR10 gene and its RNA expression in a range of 
horse tissues. It describes the phylogenetic analysis of the Equine TLR1,6,10,2 annotations in the horse genome, firmly 
identifying them in their corresponding gene clades compared to other species and firmly placing the horse gene 
with other TLR10 genes from odd-toed ungulates. Additional 3’ transcript extensions to that annotated for TLR10 in 
the horse genome have been identified by analysis of RNAseq data. RNA expression of the equine TLR10 gene was 
highest in peripheral blood mononucleocytes and lymphoid tissue (lymph nodes and spleen), however some expres-
sion was detected in all tissues tested (jejunum, caudal mesenteric lymph nodes, bronchial lymph node, spleen, lung, 
colon, kidney and liver). Additional data on RNAseq expression of all equine TLR genes (1–4 and 6–10) demonstrate 
higher expression of TLR4 than other equine TLRs in all tissues.
Conclusion: The equine TLR10 gene displays significant homology to other mammalian TLR10 genes and could be 
reasonably assumed to have similar fuctions. Its RNA level expression is higher in resting state PBMCs in horses than in 
other tissues.
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Background
The toll-like receptors (TLRs) are a family of membrane 
receptors that recognise a wide range of pathogen asso-
ciated molecular patterns (PAMPs) and are considered 
a crucial signaling component of the innate immune 
system. TLRs 1-13 have previously been identified in 
mammals [1]. These genes have a distinctive structure 
consisting of an extracellular amino-terminal leucine-
rich repeat (LRR) domain, responsible for ligand binding, 
a transmembrane domain, and an intracellular carboxyl 
terminal toll/IL (interleukin)-1 receptor domain (TIR) 
that is responsible for signal transduction. Most TLR 
genes have no introns within their TIR domains. The 
genetic structure of these genes usually consists of a large 
5′ exon containing the TIR and or the LRR domains with 
or without smaller exons at the 3′ end of the gene, often 
containing non-coding regions [2].
Based on genetic sequence TLRs can be broadly 
divided into six subfamilies that have related PAMP rec-
ognition and signaling pathways (TLR1/2/6/10, 3, 4, 5, 
7/8/9 and 11/12/13). TLRs 3 and 7/8/9 are located intra-
cellularly and respond to bacterial and viral nucleic acids, 
inducing expression of type I interferons. TLR 1/2/6/10 
and 4, 5 are expressed on the cell surface and sense cell 
wall and outer membrane components of bacterial, fun-
gal and protozoal organisms activating a core signaling 
pathway including NFκB and other transcription factors 
leading to pro-inflammatory cytokine release [3].
In the horse, the sequences of TLR 1–4 and 6–9 have 
been described [4–6] with some studies describing expres-
sion levels of some classes of TLRs in individual tissues or 
disease states [4, 5, 7–12]. The presence of equine TLR5 is 
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controversial. Its existence has been suggested by cytokine 
release in response to bacterial flagellin, the ligand for 
TLR5 [10] and a recent report of a 454 bp fragment with 
high sequence similarity to the intracellular signaling 
domain of human TLR5 in an equine expressed sequence 
tag [13]. However, no full length homologue has been 
identified in the published equine genome.
TLR10 is currently the only orphan receptor without a 
known ligand, or conclusive biological function. A pseu-
dogene in rodents [14], and full length TLR10 genes have 
been identified in a range of mammals, including humans 
[15], sheep [16], cattle [17] and pigs [18]. TLR10 is pre-
sent as part of a 50  kb TLR6-TLR1-TLR10 gene cluster 
thought to have arisen by ancestral gene duplication 
events. These TLR1 subfamily proteins form heterodi-
mers with TLR2 [3, 19] with varying ligand affinity.
TLR10 is known to be expressed in humans in a wide 
range of lymphoid tissues and cells, as well as in intesti-
nal epithelial cells, dermal endothelial cells and placental 
trophoblasts [20–23]. TLR10 RNA expression has also 
been detected in pigs, cattle and sheep, primarily in lym-
phoid tissue such as peripheral blood leukocytes, lymph 
nodes and spleens, though trace levels of RNA have been 
detected in other tissues (Additional file 1: Table S1). Ini-
tial modeling studies have suggested that di and triacety-
lated lipopeptides may potentially interact with TLR10/1, 
TLR10/2 hetero-dimers and TLR10/10 homodimers [19]. 
Co-immunoprecipitation experiments confirmed that, 
similar to TLR2/1, TLR2/10 complexes recruit the proxi-
mal adaptor MyD88 to the activated receptor complex. 
However, human TLR10, alone or in cooperation with 
TLR2, fails to activate typical TLR-induced signalling (such 
as NF-kB activation) downstream of the adapter molecules 
[3]. The role of TLR10 in inflammation is controversial. 
TLR10 has been shown to mediate the inflammatory 
response in human intestinal epithelial cells and mac-
rophages to intracellular Listeria monocytogenes infection 
in one study [24]. While another study, using RNA silenc-
ing, blocking antibody and transfection suggests inhibitory 
properties leading to an anti-inflammatory effect [25].
There has been only one published report on TLR10 
expression in the horse. This report used semi-quantita-
tive PCR, based on predicted sequences, and suggested 
TLR10 expression in equine bronchial epithelium [26]. 
To extend this understanding, this paper presents an ini-
tial description of the transcriptional profile of TLR10 in 
a variety of tissues in the horse, along with the previously 
described equine TLR genes.
Methods
Tissue samples for RNAseq: details of these samples, 
generation of RNAseq data and mapping to the horse 
genome have been published previously [27, 28]. Briefly, 
the samples consisted of five tissue samples (kidney, 
jejunum, liver, spleen and mesenteric lymph node) col-
lected from an aged gelding, lymphocytes isolated by 
Ficoll Paque (GE healthcare) from a healthy 11 year old 
welsh mountain pony gelding and RNA from lympho-
cytes isolated from a healthy thoroughbred mare (the 
same horse whose DNA the horse genome is derived 
from) (Additional file  1: Table S2). The RNA samples 
were extracted, prepared and sequenced on a SOLiD 3 
ABi sequencer to generate 50 bp reads. These reads were 
mapped to the equine reference genome EquCab2 and 
the transcriptome data was generated as in Moreton et al. 
[27]. The data for the TLR genes was retrieved from the 
annotated transcriptome [data available at EBI sequence 
read archive (SRA) under the study accession number 
ERP001116 and at 10.7717/peerj.382/supp-6]. Relative 
expression is given as reads per kilobase per million reads 
(RPKM) [29].
Tissue samples for RT-qPCR based TLR10 expres-
sion analysis: Samples were collected post mortem from 
healthy animals euthanized for other reasons than this 
study. Approximately 5  mm3 tissue samples (kidney, 
spleen, liver, colon, lung, bronchial and mesenteric lymph 
nodes) were collected and stored in RNA later (Addi-
tional file 1: Table S2). Biopsies were homogenised using 
a 5 mm stainless steel ball-bearing in a Retsch® Bead Mill 
MM 301 at 30 shakes per second for 4 min (colon, lung, 
bronchial and mesenteric lymph nodes), 5  min (spleen) 
or 6  min (liver and kidney), RNA extraction was per-
formed using the Nucleospin RNA II mini kit (Machery 
Nagel) according to manufacturer’s instructions. RNA 
was converted to cDNA using random hexamer primers 
(promega) and M-MLV reverse transcriptase (promega) 
as per manufacturer’s instructions. RNA quality was 
determined using RNA 6000 Nano Kit® Bioanalyser (Agi-
lent technologies, Waldbronn, Germany), for RNA integ-
rity numbers (RIN) see Additional file 1: Table S2. A cut 
off value of a RIN of 5 was set as the quality threshold for 
a sample to be included in the study as recommended for 
qPCR studies in Fleige and Pfaffl [30].
Tissues from all horses were considered to be in a “rest-
ing” state without obvious gross pathology.
For each predicted TLR like horse gene the long-
est open reading frame was translated and aligned with 
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known TLR1,2,6 and 10 proteins from Swissprot. All 
known vertebrate TLR10 genes were identified and pre-
dicted protein sequences were identified. In each case, 
sequences were aligned using Muscle and a phyloge-
netic tree generated using PhyML under the LG model 
with 4 rate classes and NNI tree searching and 100 boot-
strap replicates. The resulting trees were visualised using 
Figtree (http://tree.bio.ed.ac.uk/software/figtree/).
All quantitative reverse transcriptase real time 
PCR (RT-qPCR) experiments were designed and per-
formed to comply with the quality controls detailed 
in the MIQE guidelines [31]. SYBR green RT-qPCR 
was performed on cDNA using primer sets for TLR10 
and reference genes succinate dehydrogenase complex 
subunit A (SDHA) and Hypoxanthine phosphoribo-
syl transferase (HPRT) (Additional file  1: Table S3). 
Specificity of the PCR amplicons was confirmed by 
sequencing.
The Light Cycler 480 DNA SYBR green 1 master mix 
(Roche) in a 20  μl reaction volume was used accord-
ing to manufacturer’s instructions. Cycling conditions 
consisted of 98  °C for 15 min then 45 cycles of 98  °C for 
15 s, 58 °C for 30 s and 72 °C for 30 s. Reactions were per-
formed on a Light Cycler 480 96 well plate real time PCR 
system (Roche). Serial dilutions of control cDNA were 
used to assess primer efficiency. Relative expression was 
calculated using the following formula [32]: Corrected Ct 
value = Ct + (Nt – Ct′) * S/S′ where Ct = mean sample Ct, 
Nt = experimental reference gene mean, Ct′ = mean refer-
ence gene of sample, S = TLR slope, S′ =  reference gene 
slope.
Results
Transcripts with (RPKM  >  0) were identified for 
TLR1-4 and TLR6-9 as well as TLR10, the latter has not 
been reported previously. The Ensembl Equus cabal-
lus database does not contain any annotations for 
TLR5. By comparison to known TLR1,6 and 10 protein 
sequences, two horse TLR1 transcripts were identified 
(ENSCAT00000002340 and rmCuff_TCONS_00039270) 
and single transcripts for TLR6 (ENSCAT00000001932) 
and TLR10 (ENSCAT00000022185).
Comparison of Equine transcripts to representa-
tive TLR1,2,6 and 10 genes shows the clear defini-
tion of ENSECAT00000002340 as equine TLR1, 
ENSECAT00000019013 as TLR2, ENSECAT00000001932 
as TLR6 and ENSECAT00000022185 as TLR10 (Fig.  1). 
When TLR10 transcript ENSECAT00000022185 is aligned 
with representatives of vertebrate TLR10 sequences it is 
most closely related to the wild Przewalski horse (E. ferus 
przewalskii) and the southern white rhinoceros (Ceratoth-
erium simum simum) and all odd-toes ungulates (Perisso-
dactyla) (Fig. 2) as would be expected.
Sufficient read depth was available for transcript struc-
ture analysis for TLR10 (Fig.  3a). Gaps in the predicted 
transcripts compared with the ENSEMBL annotations over 
the 5′ exons are probably due to sub-optimal read cover-
age rather than real transcriptional variation. Additional 
3′ transcript extensions are suggested by our transcript 
analysis when compared with the reference sequence anno-
tations (Fig.  3a). The sequence covered by our predicted 
TLR10 transcript contains one large open reading frame 
with a short leader sequence. Basic structural domain anal-
ysis of this open reading frame using the SMART protein 
domain analysis suite demonstrated a typical mammalian 
TLR10 gene structure (Fig.  3b) consisting of a series of 
amino terminal LRR’s, a Leucine Rich Repeat C—terminal 
domain, a transmembrane domain and a carboxyl terminal 
TIR domain. Read depth was not consistently high enough 
for confident calling of SNPs on TLR10.
Each organ or cell type was found to have a distinct TLR 
expression profile (Additional file 2: Figure S1). Absolute 
TLR expression was highest in the lymphocyte samples 
(Additional file  2: Figure S1 A and B). Both lymphocyte 
samples had similar patterns of TLR expression with 
TLR4 expressed at the highest level (26  <  RPKM  <  70) 
followed by TLR2 and TLR1. TLR’s 6, 7, 8 and 10 were 
expressed at low levels (RPKM  <  12) and TLR3 at trace 
levels (RPKM < 1). Apart from expression of TLR4 and 8 
in the spleen, expression of any TLR in other tissues was 
at low or trace levels (RPKM < 5). Total number of reads 
and reads mapped per tissue were similar (Additional 
file 1: Table S2), indicating that the differences in RPKM 
reads for this class of gene is genuine and not due to dif-
ferences in general read mapping density across tissues.
RNAseq data for TLR10 expression were very low in 
tissues other than PBMCs (Additional file 2: Figure S1). 
To confirm TLR10 mRNA expression from the RNAseq 
data, a range of tissues from further Thoroughbred 
Horses and Welsh Ponies were analyzed by RT-qPCR. 
TLR10 transcript was detected in all tissues tested: cau-
dal mesenteric lymph nodes, bronchial lymph node, 
spleen, lung, colon, kidney and liver; with highest levels 
in the lymphoid tissues (lymph nodes and spleen) and 
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lowest in liver (Fig. 4). Where samples for multiple horses 
were available for that tissue, TLR10 transcript levels 
were consistent within that tissue (Fig. 4a).
Discussion
In summary, equine TLR10 shows conserved domain 
architecture and high sequence similarity to its mammalian 
counterparts. Equine TLR10 mRNA is expressed in a wide 
range of tissues with highest levels in lymphoid tissues.
The similarity of the predicted Equine TLR10 pro-
tein with the other described mammalian TLR10’s [33]) 
implies functional conservation between the equine 
and other TLR10’s. Our transcriptome assembly and 
annotation would suggest additional 3′ exons to the 
reference genome annotation for equine TLR10. These 
extensions may be tissue specific and remain to be con-
firmed with Sanger sequencing of mRNA.
The transcription profile for the complete TLR reper-
toire in the normal horse tissues examined here would 
also additionally suggest that TLR4 is an important sen-
tinel signaling molecule in horse lymphoid tissue (spleen 
and PBMCs). This would correlate with the known sus-
ceptibility of horses to bacterial LPS (the ligand for 
TLR4) [34].
Fig. 1 Phylogenetic tree of TLR1,2 6,10 gene family. Comparison of the horse TLR transcripts identified in this study with known TLR1,2,6 and 10 
protein sequences. Accession numbers of sequences are contained in Additional file 1: Table S4. Sequences were aligned using Muscle and an 
unrooted phylogenetic tree generated using PhyML (100 bootstrap replicates). For clarity, only bootstrap values above 80 % are shown
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Conclusion
The results presented here demonstrate transcription of 
TLR10 in the horse in a wide range of tissues with expres-
sion location and levels similar to that in other mammalian 
species (Additional file 1: Table S1). This paper provides a 
starting point for further studies of activities of this gene in 
the horse. Presumably given it’s homology with TLR10 in 
other species it is likely to form heterodimers with TLR2, 
however confirmation of the function of TLR10 in any 
mammalian species will require further work.
Fig. 2 Phylogenetic tree of vertebrate TLR10 genes: Sequences were aligned using muscle and an unrooted phylogenetic tree generated using 
PhyML (100 bootstrap replicates). Bootstrap values are shown for each node. Species are identified by latin name and accession number. Details of 
sequences are contained in Additional file 1: Table S5
Fig. 3 Schematic diagram of equine TLR10 transcript and protein structure. a eqTLR10 transcript structure: Red  Ensembl annotation (EquCab2), 
Blue predicted transcript structure from this study, lines predicted introns, boxes and arrows predicted exons, arrows indicate direction of transcrip-
tion. b Predicted Protein domain architecture equine TLR10. Domain diagram generated using SMART (http://smart.embl-heidelberg.de/). LRR leu-
cine rich repeat, LRRCT leucine rich repeat C-terminal domain, Blue line transmembrane domain, TIR carboxyl terminal Toll/IL (interleukin)-1 receptor 
domain
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Fig. 4 TLR10 expression in healthy equine tissues. a TLR10 expression determined by RT-qPCR. Samples from caudal mesenteric lymph nodes 
(MSN, n = 12), Bronchial lymph node (LN, n = 1), spleen (n = 2), lung (n = 1), colon (n = 4), kidney (n = 3) and liver (n = 3) were collected post 
slaughter/euthanasia and preserved in RNALater prior to RNA isolation, cDNA synthesis and RT-qPCR. TLR10 expression has been normalized to two 
house keeping genes, SDHA and HPRT and is expressed as 40-CT, mean is shown as horizontal line. ND = not determined (tissue not available) b 
TLR10 expression across different tissues in 3 individual horses where multiple tissue samples were available (these horses are also included in part 
A)
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